Corvus Pharmaceuticals In... (CRVS)
NASDAQ: CRVS
· Real-Time Price · USD
7.19
0.15 (2.13%)
At close: Oct 03, 2025, 3:59 PM
6.90
-4.03%
After-hours: Oct 03, 2025, 05:34 PM EDT
2.13% (1D)
| Bid | 6.65 |
| Market Cap | 535.76M |
| Revenue (ttm) | 88K |
| Net Income (ttm) | -45.13M |
| EPS (ttm) | -1.08 |
| PE Ratio (ttm) | -6.66 |
| Forward PE | -11.93 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.4 |
| Volume | 1,327,435 |
| Avg. Volume (20D) | 583,676 |
| Open | 7.04 |
| Previous Close | 7.04 |
| Day's Range | 6.77 - 7.38 |
| 52-Week Range | 2.54 - 10.00 |
| Beta | 0.56 |
| Ex-Dividend Date | n/a |
About CRVS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CRVS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CRVS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+32.24%
Corvus Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
4 months ago
+4.69%
Corvus Pharmaceuticals shares are trading higher after it reported Q1 EPS. Company also reported data from its Cohorts 1-3 of Placebo-Controlled phase 1 clinical trial
1 month ago · seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call TranscriptCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Leiv Lea - Chief Financial Officer Richard A. Miller - Co-Founder, President...